Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A LEVINE

Showing results (211-220 of 218) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 218 results.
The Journal of Clinical Endocrinology and Metabolism|March 20, 1999
Familial dwarfism due to a novel mutation of the growth hormone-releasing hormone receptor geneR Salvatori, C Y Hayashida, M H Aguiar-Oliveira, et al.
The Journal of Clinical Endocrinology and Metabolism|November 24, 1999
Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinomaM D Ringel, P L Balducci-Silano, J S Anderson, et al.
Clinical Chemistry|June 3, 1999
Quantitative reverse transcription-PCR measurement of thyroglobulin mRNA in peripheral blood of healthy subjectsS T Wingo, M D Ringel, J S Anderson, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 5, 2002
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosisR Rizzoli, S L Greenspan, G Bone, et al.
American Journal of Preventive Medicine|July 1, 1996
Teaching dietary counseling skills to residents: patient and physician outcomes. The CADRE Study GroupA T Evans, L Q Rogers, J G Peden, et al.
Calcified Tissue International|May 16, 2001
Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcomaA B Sparks, S N Peterson, C Bell, et al.
The Journal of Clinical Endocrinology and Metabolism|November 24, 1999
Effect of severe growth hormone (GH) deficiency due to a mutation in the GH-releasing hormone receptor on insulin-like growth factors (IGFs), IGF-binding proteins, and ternary complex formation throughout lifeM H Aguiar-Oliveira, M S Gill, E S de A Barretto, et al.
Aging (Milan, Italy)|April 4, 2000
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study GroupT Schnitzer, H G Bone, G Crepaldi, et al.
Pageof 22

Showing results (211-220 of 218) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 218 results.
The Journal of Clinical Endocrinology and Metabolism|March 20, 1999
Familial dwarfism due to a novel mutation of the growth hormone-releasing hormone receptor geneR Salvatori, C Y Hayashida, M H Aguiar-Oliveira, et al.
The Journal of Clinical Endocrinology and Metabolism|November 24, 1999
Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinomaM D Ringel, P L Balducci-Silano, J S Anderson, et al.
Clinical Chemistry|June 3, 1999
Quantitative reverse transcription-PCR measurement of thyroglobulin mRNA in peripheral blood of healthy subjectsS T Wingo, M D Ringel, J S Anderson, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 5, 2002
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosisR Rizzoli, S L Greenspan, G Bone, et al.
American Journal of Preventive Medicine|July 1, 1996
Teaching dietary counseling skills to residents: patient and physician outcomes. The CADRE Study GroupA T Evans, L Q Rogers, J G Peden, et al.
Calcified Tissue International|May 16, 2001
Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcomaA B Sparks, S N Peterson, C Bell, et al.
The Journal of Clinical Endocrinology and Metabolism|November 24, 1999
Effect of severe growth hormone (GH) deficiency due to a mutation in the GH-releasing hormone receptor on insulin-like growth factors (IGFs), IGF-binding proteins, and ternary complex formation throughout lifeM H Aguiar-Oliveira, M S Gill, E S de A Barretto, et al.
Aging (Milan, Italy)|April 4, 2000
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study GroupT Schnitzer, H G Bone, G Crepaldi, et al.
Pageof 22